Concepts (67)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 2 | 2017 | 282 | 0.240 |
Why?
|
| Diabetic Nephropathies | 5 | 2010 | 228 | 0.210 |
Why?
|
| African Americans | 4 | 2010 | 1435 | 0.180 |
Why?
|
| Plasminogen Activators | 1 | 2000 | 1 | 0.160 |
Why?
|
| Sickle Cell Trait | 2 | 2010 | 14 | 0.160 |
Why?
|
| Vascular Patency | 1 | 2000 | 71 | 0.160 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2000 | 46 | 0.160 |
Why?
|
| Catheters, Indwelling | 1 | 2000 | 44 | 0.160 |
Why?
|
| Thrombolytic Therapy | 1 | 2000 | 67 | 0.160 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2000 | 48 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 2000 | 71 | 0.160 |
Why?
|
| Heparin | 1 | 2017 | 74 | 0.130 |
Why?
|
| European Continental Ancestry Group | 2 | 2010 | 1176 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2017 | 143 | 0.120 |
Why?
|
| Proteinuria | 3 | 2010 | 55 | 0.100 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2010 | 38 | 0.100 |
Why?
|
| Vital Signs | 1 | 2011 | 10 | 0.090 |
Why?
|
| Molecular Motor Proteins | 1 | 2010 | 60 | 0.080 |
Why?
|
| Myosin Heavy Chains | 1 | 2010 | 89 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2010 | 1523 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 35 | 0.080 |
Why?
|
| Diabetic Retinopathy | 1 | 2010 | 72 | 0.080 |
Why?
|
| Nephrotic Syndrome | 1 | 2007 | 12 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2010 | 529 | 0.070 |
Why?
|
| Middle Aged | 8 | 2017 | 12703 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2007 | 57 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 439 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2011 | 3812 | 0.060 |
Why?
|
| Male | 8 | 2017 | 20697 | 0.050 |
Why?
|
| Female | 8 | 2017 | 21490 | 0.050 |
Why?
|
| Nuclear Family | 1 | 2002 | 15 | 0.050 |
Why?
|
| Aged | 5 | 2011 | 10998 | 0.050 |
Why?
|
| Humans | 9 | 2017 | 34474 | 0.040 |
Why?
|
| Life Tables | 1 | 2000 | 6 | 0.040 |
Why?
|
| Adult | 4 | 2011 | 10015 | 0.040 |
Why?
|
| Thrombosis | 1 | 2000 | 88 | 0.040 |
Why?
|
| Academic Medical Centers | 2 | 2011 | 168 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 4150 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 3 | 2010 | 548 | 0.030 |
Why?
|
| Biopsy | 2 | 2010 | 268 | 0.030 |
Why?
|
| Albuminuria | 2 | 2010 | 181 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 2 | 2010 | 315 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 2461 | 0.020 |
Why?
|
| Patient Admission | 1 | 2011 | 59 | 0.020 |
Why?
|
| Homozygote | 1 | 2010 | 59 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 79 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2011 | 207 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 801 | 0.020 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2007 | 3 | 0.020 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2007 | 6 | 0.020 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2007 | 4 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 808 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 28 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 48 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2007 | 90 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 849 | 0.020 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2007 | 132 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 274 | 0.010 |
Why?
|
| North Carolina | 1 | 2010 | 1612 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 1506 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 2825 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 3799 | 0.010 |
Why?
|
| Creatinine | 1 | 2002 | 206 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 4136 | 0.010 |
Why?
|
| Obesity | 1 | 2007 | 1244 | 0.010 |
Why?
|
| Prevalence | 1 | 2002 | 1034 | 0.010 |
Why?
|